SCHEMBL2865557

SCHEMBL2865557

CC(C)(C)OC(=O)Nc1ccc(Oc2ccnc(C(N)=O)c2)cc1F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 3/20 0.52
MAPK14 Q16539 11/20 0.48
KDR P35968 6/20 0.47
BRAF P15056 4/20 0.47
MAPK13 O15264 3/20 0.47
RAF1 P04049 3/20 0.47
FLT1 P17948 3/20 0.47
RIPK2 O43353 2/20 0.47
RET P07949 2/20 0.47
KIT P10721 2/20 0.47
BCR P11274 2/20 0.47
FGFR1 P11362 2/20 0.47
PDGFRA P16234 2/20 0.47
EPHA1 P21709 2/20 0.47
TTK P33981 2/20 0.47
FLT4 P35916 2/20 0.47
FLT3 P36888 2/20 0.47
MAPKAPK2 P49137 2/20 0.47
CLK1 P49759 2/20 0.47
LIMK1 P53667 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29834707 0.90 ABL1 (0.51) ABL1MAPK14KDRBRAFMAPK13
SCHEMBL29834756 0.89 ABL1 (0.53) ABL1MAPK14KDRBRAFMAPK13
SCHEMBL29834639 0.89 ABL1 (0.50) ABL1MAPK14KDRBRAFMAPK13
SCHEMBL29834780 0.88 ABL1 (0.64) ABL1MAPK14KDRBRAFMAPK13
SCHEMBL1137179 0.87 ABL1 (0.54) ABL1MAPK14KDRBRAFMAPK13
SCHEMBL2858354 0.87 MAPK14 (0.63) ABL1MAPK14KDRBRAFMAPK13
SCHEMBL105737 0.85 KDR (0.42) ABL1KDRBRAFRAF1FLT1
SCHEMBL30729902 0.85 MAPK14 (0.53) ABL1MAPK14KDRBRAFMAPK13
SCHEMBL16895218 0.85 MAPK14 (0.53) ABL1MAPK14KDRBRAFMAPK13
SCHEMBL24037398 0.84 MAPK14 (0.48) ABL1MAPK14KDRBRAFMAPK13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100311972-A1 METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-12-09 US disclosed
US-20100311972-A1 METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-12-09 US disclosed
US-20100311972-A1 METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-12-09 US disclosed
EP-2248810-A1 METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2010-11-10 EP disclosed
WO-2009104520-A1 METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE エーザイ・アール・アンド・ディー・マネジメント株式会社 (JP) 2009-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311972-A1 METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE TET2, QDPR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 ABL1 51/4885MAPK14 1986/4885KDR 2284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.